Drug Profile
Research programme: anticancer phenylarsonic acid derivatives - Parker Hughes
Alternative Names: anticancer phenylarsonic acid derivatives research programme - Parker HughesLatest Information Update: 25 Aug 2006
Price :
$50
*
At a glance
- Originator Parker Hughes Institute
- Class
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 25 Aug 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 01 Aug 2003 Preclinical trials in Cancer in USA (unspecified route)